Denmark · Series A startup

Who invested in STipe Therapeutics

One round we have observed, with the 6 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 26 Oct 2026

$22Mraised across 1 round since 2019, from 1 source

Latest round
Series A, $22MSept 2019
Led by
Novo Seeds and Arix Bioscience
Investors
6 (2 led)
See who backed them

The rounds

  1. Sept 2019
    Series A$22M

    Reported by FinSMEs

Everyone who backed them

Novo SeedsVC firm1round, led 1
Arix BioscienceVC firm1round, led 1
Novo HoldingsVC firm1round
Wellington PartnersVC firm1round
Sunstone LSV General Partner IV ApSno record of our own yet1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about STipe Therapeutics

Who invested in STipe Therapeutics?

STipe Therapeutics's investors include Novo Seeds, Arix Bioscience, Novo Holdings, Wellington Partners and BioInnovation Institute, and 1 more on record. Novo Seeds led its latest round.

How much has STipe Therapeutics raised?

STipe Therapeutics has raised $22M across 1 round since 2019.

When did STipe Therapeutics last raise?

STipe Therapeutics's most recent round was a Series A of $22M in Sept 2019, led by Novo Seeds.

What was STipe Therapeutics's biggest round?

Its most recent round, $22M in Sept 2019, is also its largest on record.

Who backed STipe Therapeutics first?

STipe Therapeutics's first round on record, in Sept 2019, was backed by Novo Seeds, Arix Bioscience and Novo Holdings and 3 others.

What stage is STipe Therapeutics at?

STipe Therapeutics's latest named round is a Series A, in Sept 2019.

Where is STipe Therapeutics based?

STipe Therapeutics is based in Denmark.

Who led STipe Therapeutics's rounds?

Novo Seeds led the Series A in 2019.

Companies like STipe Therapeutics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.